Phase 1 Study To Assess the Safety and Tolerability of Human Embryonic Stem Cell-Derived Midbrain Dopamine Neuron Cell Therapy (MSK-DA01) For Advanced Parkinson's Disease

  • STATUS
    Not Recruiting
  • sponsor
    BlueRock
Updated on 25 June 2022
dopamine
dyskinesia

Summary

Dopamine neurons made from stem cells are injected into the brain under general anesthesia. Subjects then take medicines to partially suppress their immune system (aimed to prevent the body from rejecting the cells) for 1 year. All subjects receive the treatment (i.e. there is no placebo group in this study).  Safety, tolerability, evidence of cell survival (using scans of the brain), and the effect on Parkinson's disease symptoms are assessed for 2 years post-transplant

Description


Details
Condition Cell Therapy, dopamine, stem cells, surgery, stem cell, neurosurgery, Parkinson's disease, neurology
Clinical Study IdentifierTX278586
SponsorBlueRock
Last Modified on25 June 2022

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note